Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Goserelin × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 39 Breast Neoplasms 28 Breast Neoplasms, Male 3 Neoplasm Metastasis 2 Infertility 2 Advanced Breast Cancer 2 Sexual Dysfunction, Physiological 1 Recurrence 1 Primary Ovarian Insufficiency 1 Osteoporosis 1 Osteitis Deformans 1 Neoplasms 1 Leiomyoma 1 Hot Flashes 1 Hemorrhage 1 Breast Cancer Invasive 1 Anemia 1 Advanced Prostate Cancer 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00439751 2016-07-12

ELAAT

Ontario Clinical Oncology Group (OCOG)

Phase 3 Completed

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡